Pricing & Market Access Outlook 2014

Pricing and market access are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need, becomes infinitely harder to assess.

The IMS Health Pricing & Market Access (P&MA) Outlook report is an annual in-depth look at the major issues shaping the payer and reimbursement environment for global pharma products. Marc Benoff, vice-president of IMS Consulting Group and global lead of P&MA, describes P&MA as “a central gear in a large and connected machine” that “will need to leverage its strategic voice, building and communicating value by linking science to customers and powering the industry through these challenging times.”

The 2014 edition contains 11 articles, selected and written by a team of in-house consultants, organized around four main themes and in what Benoff describes as a spirit of dialogue.

Recalibrating the pharma mindset: New challenges invariably necessitate an organizational rethink and greater cross-functional collaboration across the global enterprise

o Organizational stress test: Is your company fit for payer purpose?

o Integrating patient journeys and funding flows

o Balancing geographic priorities in clinical trial design

Partnering opportunities: A more integrated healthcare environment creates new opportunities for partnership among a wide range of stakeholders.

o Beyond the pill: Two truths and a lie

o Rethinking RWE: Partnering with payers

Funding challenges: Greater pressure on healthcare budgets and widespread healthcare reform is transforming the global insurance market and creating new rules for successful premium pricing.

o Exchanges: Should pharma care?

o Private insurance as an access lever in emerging markets

o List price premiums in US and EU: What are the implications?

o Payment by use: A new value paradigm for oncology

Shifting sands: The recent focus on specialty drugs may have obscured the gains still to be had from primary care and biosimilars.

o Opportunity hidden in plain sight: A return to primary care

o Mind the gap: Expectation versus reality in the EU biosimilar market

“P&MA will need to leverage its strategic voice, building and communicating value by linking science to customers and powering the industry through these challenging times”

Please fill out the form below to obtain your free copy of the White Paper.

For more information on IMS Consulting Group please visit:

www.imsconsultinggroup.com